HOME >> MEDICINE >> NEWS
Positive results for ACRUX's lead product in US Phase 3 trial

Acrux (ASX: ACR), the pharmaceutical company with unique technology for delivering drugs through the skin, today announced positive results in a US Phase 3 clinical trial of Evamist, its daily skin spray for prevention of symptoms associated with menopause. The trial was conducted by its US commercial partner VIVUS Inc. (NASDAQ: VVUS), which will now proceed to file a marketing application with the US Food and Drug Administration (FDA) in the second half of 2006.

Evamist is the most advanced commercial application of Acrux's patented delivery technology; if the FDA approves VIVUS' marketing application, Acrux's first product could be available to women in the USA in the second half of 2007. Several other products that use the same delivery technology are following close behind. The positive result of this Phase 3 trial is therefore a pivotal milestone for each of these products.

The Phase 3 trial assessed the safety and efficacy of Evamist for the treatment of hot flushes in menopausal women. The trial was a 12-week study of 457 menopausal women, conducted under a Special Protocol Assessment (SPA) from the FDA. Results showed that the most effective Evamist dose decreased the number of hot flushes by 78%. The reduction in frequency and severity of moderate to severe hot flushes was statistically significant compared with placebo for all three doses of Evamist evaluated.

Importantly, application site irritation was less than 1% and was mild in nature. The results from the trial will be discussed by VIVUS at an Analyst Day in New York on 18 May 2006.

"We believe these positive trial results along with this novel patient-preferred transdermal delivery system will establish Evamist as a superior estrogen therapy for the treatment of menopausal symptoms," stated Leland Wilson, president and chief executive officer for VIVUS. "We have worked diligently toward the development of this unique and easy-to-use product, and we are thrilled with
'"/>

Contact: Igor Gonda
61-38-379-0100
Research Australia
9-May-2006


Page: 1 2

Related medicine news :

1. Positive results more likely from industry-funded breast cancer trials
2. M. D. Anderson reports first drug activity in T315I-Positive CML, ALL and JAK-2-Positive MPD
3. Positive parenting helps encourage healthy sun habits in children
4. Positive outcome of Medicare drug benefit
5. Positive study results for methylphenidate transdermal system
6. Positive study results for methylphenidate transdermal system
7. Stem cell transplantation procedure results in long-term survival for amyloidosis patients
8. GSKs Pazopanib shows positive results in patients with advanced renal cell carcinoma
9. GSKs Pazopanib shows positive results in patients with advanced RCC and ovarian cancer
10. Targeted, oral agent Enzastaurin shows favorable results
11. Childhood obesity intervention shows promising results

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Positive results for ACRUX lead product Phase trial

(Date:9/2/2015)... ... 2015 , ... Pentec Health, Inc., a national leader in outsourced pharmacy services, ... consecutive year. Less than 5 % of this year’s 5000 honorees share the “six-time” ... Pentec’s 3-year revenue growth rate of 65% sustained its most recent achievement. As an ...
(Date:9/2/2015)... ... September 02, 2015 , ... Dr. Robert G. ... he is now certified in “Systema”: a Russian martial art system that is also ... , Systema , which dates back to the 10th century, is a ...
(Date:9/2/2015)... ... September 02, 2015 , ... Mobile working is increasingly more important, as business ... everywhere new mobile apps are being launched, and mobile device usage as a whole ... of their work and personal lives. What's more people are expecting mobile versions of ...
(Date:9/1/2015)... Spring Lake, NJ (PRWEB) , ... September 01, ... ... physician, has a reputation for the telling the truth about medicine and health, ... has created a video blog, where he plans to regularly debunk certain misconceptions ...
(Date:9/1/2015)... Paul- Eagan (PRWEB) , ... September 01, 2015 , ... For many men, the first ... chin. Men were often forced to wear a looser fitting shirt with a collar ... their neck, sliding a finger between their collar and skin all day because it’s uncomfortable. ...
Breaking Medicine News(10 mins):Health News:Pentec Health Once Again Named One of the Fastest-Growing Private Companies in America 2Health News:Dr. Robert G. Schwartz Achieves Certification in Russian Martial Art “Systema” and Focuses on Integrating Techniques & Principles into Health Care Delivery 2Health News:Dr. Robert G. Schwartz Achieves Certification in Russian Martial Art “Systema” and Focuses on Integrating Techniques & Principles into Health Care Delivery 3Health News:New Mobility Experience From Winscribe 2Health News:New Mobility Experience From Winscribe 3Health News:Dr. Michael Rothman, NJ’s Leading Holistic Doctor, Presents a Video Blog that Discusses the Most Confusing and Interesting Current Medical Topics 2Health News:Getting Rid of Double Chins: New FDA Approved Kybella Treatment Proving Very Popular Among Professional Men at Crutchfield Dermatology 2
(Date:9/1/2015)... UT Southwestern Medical Center President Dr. ... U.S. Representatives Michael C. Burgess , M.D., and ... the 21 st Century Cures Act, bipartisan legislation ... the United States Senate. ... Sciences members, department chairs, center directors, and leading researchers ...
(Date:9/1/2015)... 2015  Results from an interim analysis of ... 5g of idarucizumab enabled emergency surgery to be ... with dabigatran (Pradaxa ® dabigatran etexilate mesylate). The ... of dabigatran enabled patients to be urgently brought ... 1.7 hours between administration of idarucizumab and start ...
(Date:9/1/2015)... 1, 2015 Agena Bioscience TM today announced ... , a commercial and financial hub from which many biotech ... testing laboratories in mainland China . ... Bioscience,s global sales with almost sixty MassARRAY ® Systems ... will allow us to expand our reach and foster ...
Breaking Medicine Technology:U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 2U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 3U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 4U.S. Rep. Michael C. Burgess, M.D., hosts roundtable at UT Southwestern to discuss pivotal 21st Century Cures Act and future of biomedical science 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 2New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 3New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 4New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 6New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 7New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 8New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 9Agena Bioscience Opens Office in Shanghai, China 2
Cached News: